Analytical Data
-
Gene name
ERAS
- Application
-
Alternative Names
Embryonic stem cell-expressed Ras
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q7Z444
-
Expression Region
3-230aa
-
Molecular Weight
28.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ERAS, or the enhanced recovery after surgery, has garnered significant attention in recent years due to its potential to improve surgical outcomes and patient recovery times. Research into ERAS protocols highlights the importance of a multidisciplinary approach that encompasses preoperative, intraoperative, and postoperative strategies. The focus on optimizing the patient's physiological status before surgery, minimizing surgical stress, and promoting early mobilization and nutrition postoperatively is crucial in minimizing complications and enhancing recovery. Additionally, the advent of recombinant proteins in the context of ERAS has opened new avenues for enhancing recovery processes. These proteins, which are engineered to perform specific biological functions, could play pivotal roles in reducing inflammation, promoting tissue repair, and modulating pain responses. The integration of ERAS with advanced biopharmaceuticals can potentially lead to tailored recovery strategies that cater to individual patient needs, thereby improving overall surgical outcomes. Therefore, ongoing research into the efficacy and safety of ERAS protocols combined with recombinant protein therapies remains essential, as it holds the promise of revolutionizing surgical care and patient rehabilitation in various clinical settings.
